Abich Financial Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Abich Financial Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$60.2K	Buy	+496	New	+$55.9K	0.02%	293

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abich Financial Wealth Management's AXSM Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Axsome Therapeutics (AXSM) in Q3 2025: 496 shares worth $60.2K. The stake represents 0.02% of the portfolio and ranks #293 among its holdings.

355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

Abich Financial Wealth Management held 496 shares of Axsome Therapeutics worth $60.2K as of Q3 2025.
Axsome Therapeutics was a new Abich Financial Wealth Management position in Q3 2025.
Axsome Therapeutics made up 0.02% of Abich Financial Wealth Management's portfolio in Q3 2025, its #293 holding.
355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.